DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vaprisol (Conivaptan Hydrochloride) - Summary

 
 



VAPRISOL SUMMARY

Conivaptan hydrochloride is a dual arginine vasopressin (AVP) antagonist with nanomolar affinity for human V1A and V2 receptors in vitro.

VAPRISOL ® is indicated to raise serum sodium in hospitalized patients with euvolemic and hypervolemic hyponatremia.

Important Limitations:

VAPRISOL has not been shown to be effective for the treatment of the signs and symptoms of heart failure and is not approved for this indication.

It has not been established that raising serum sodium with VAPRISOL provides a symptomatic benefit to patients.


See all Vaprisol indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Vaprisol (Conivaptan)

Hypothyroidism
Source: MedicineNet levothyroxine sodium Specialty [2017.04.25]
Title: Hypothyroidism
Category: Symptoms and Signs
Created: 2/26/2014 12:00:00 AM
Last Editorial Review: 4/25/2017 12:00:00 AM

Hypothyroidism During Pregnancy
Source: MedicineNet levothyroxine sodium Specialty [2016.02.03]
Title: Hypothyroidism During Pregnancy
Category: Diseases and Conditions
Created: 11/30/1999 12:00:00 AM
Last Editorial Review: 2/3/2016 12:00:00 AM

Myxedema coma: Causes, risk factors, and outlook
Source: Endocrinology News From Medical News Today [2017.08.04]
Myxedema is a severe form of hypothyroidism. A myxedema coma is a potentially fatal complication of this condition, with specific risks and causes.

more news >>

Published Studies Related to Vaprisol (Conivaptan)

Open-label randomized trial of the safety and efficacy of a single dose conivaptan to raise serum sodium in patients with traumatic brain injury. [2011.06]
BACKGROUND: Conivaptan is an arginine-vasopressin-receptor antagonist approved for the treatment of hyponatremia. We hypothesized that administration of conivaptan to normonatremic patients with traumatic brain injury (TBI) is safe and could reduce intracranial pressure (ICP)... CONCLUSIONS: These data suggest that a single dose conivaptan is safe in non-hyponatremic patients with severe TBI and may reduce ICP. Further studies are needed to establish the effect of conivaptan on clinically relevant endpoints, and its role in the management of intracranial hypertension.

Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia. [2011.05.01]
PURPOSE: The efficacy and safety of conivaptan administered via 30-minute i.v. infusion to patients with euvolemic or hypervolemic hyponatremia were evaluated... CONCLUSION: Conivaptan hydrochloride 20 mg, administered once or twice daily via 30-minute i.v. infusion, significantly increased SSCs over 48 hours in patients with euvolemic or hypervolemic hyponatremia when compared with placebo. Common AEs were similar to those seen with continuous conivaptan infusions.

Efficacy and Safety of Oral Conivaptan, a Vasopressin-Receptor Antagonist, Evaluated in a Randomized, Controlled Trial in Patients With Euvolemic or Hypervolemic Hyponatremia. [2009.01]
BACKGROUND:: In most cases of hyponatremia, arginine vasopressin secretion is inappropriately high. This placebo-controlled, randomized, double-blind multicenter study evaluated the efficacy and safety of oral conivaptan, a V1A/V2-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia... CONCLUSION:: Oral conivaptan was effective in increasing serum [Na] in patients with euvolemic or hypervolemic hyponatremia and had a favorable safety profile.

Intravenous conivaptan. [2008]
*Conivaptan is an arginine vasopressin V1A and V2 receptor antagonist...

Intravenous conivaptan: effects on the QTc interval and other electrocardiographic parameters in healthy volunteers. [2007.03]
Prolongation of the QT interval is clinically important because it may be associated with torsade de pointes, a potentially fatal arrhythmia. The objective of this study was to define the effects on electrocardiogram (ECG) of intravenous conivaptan, the first arginine vasopressin V1A/V2-receptor antagonist indicated for the treatment of euvolemic hyponatremia, on hospitalized patients without congestive heart failure...

more studies >>

Clinical Trials Related to Vaprisol (Conivaptan)

Study of the Safety and Efficacy of Conivaptan (Vaprisol�) to Raise Serum Sodium Levels in Patients With Severe Traumatic Brain Injury [Completed]
The investigators plan to utilize conivaptan (Vaprisol) to promote isolated water loss, in combination with normal (physiologic) fluid replacement to maintain a normal blood volume status, in patients with severe TBI. The goal of this therapy is to raise blood sodium in a controlled fashion in subjects with severe TBI, and reduce the use of hypertonic saline infusion. We hypothesize that this therapy will maintain a stable state of high blood sodium, while decreasing the overall sodium load needed to achieve these goals.

Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion [Withdrawn]
Heart Failure is a growing and challenging public health concern in the United States. Heart failure commonly manifests as a syndrome of salt and water retention. Arginine vasopressin is a peptide hormone that is intimately involved in salt and water homeostasis. AVP is released into the circulation in response low blood volume and hypernatraemia. Despite fluid overload, vasopressin levels are often inappropriately elevated in patients with heart failure and LV dysfunction. Data suggest that vasopressin may also contribute to the deleterious circulatory response in patients with heart failure and play a role in the development and progression of the disease process. In their study, Udelson et al. showed that vasopressin receptor antagonism with Conivaptan resulted in significant diuresis with stable hemodynamics in advanced heart failure patients. Currently Intravenous diuretics and vasodilators are the standard of care in treating patients with acute decompensated heart failure. We will be studying the renal and diuretic effects of add on therapy with intravenous Conivaptan in patients receiving intravenous Nesiritide and intravenous diuretics.

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol�) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia [Suspended]
The objective of this study is to evaluate the efficacy, safety and pharmacokinetics of intravenous conivaptan in pediatric subjects with abnormally low concentration of sodium in blood.

Comparing the Effects of Conivaptan and Diuretics on Plasma Neurohormones and Renal Blood Flow in Patients With Chronic Congestive Heart Failure [Not yet recruiting]
The purpose of the study is to compare the effects of conivaptan and diuretics on renal blood flow and neurohormones.

Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function [Completed]
A study to compare a 48-hour continuous infusion of conivaptan in subjects with mild and moderate liver impairment versus subjects with normal liver function

more trials >>


Page last updated: 2017-08-04

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017